A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01233232 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

109

Enrollment

INDUSTRY

Sponsor class

Conditions

Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD)
Laymen Terminology Chronic Bronchitis and Emphysema

Interventions

DRUG: Placebo
DRUG: AZD5069 50mg
DRUG: AZD5069 80mg

Sponsor

AstraZeneca